《港股開市》恆指高開145點 友邦漲4% 藥明系大幅高開
美債孳息回落,道指隔晚(6日)收升141點或0.4%。港股今早(7日)繼續受中央救市憧憬刺激高開,恆指高開145點或0.9%,報16,282點;國指高開34點或0.6%,報5,507點;恆生科技指數高開25點或0.8%,報3,269點。
科技股方面,阿里-SW(09988.HK)、騰訊(00700.HK)、美團-W(03690.HK)、京東-SW(09618.HK)及網易-S(09999.HK)高開1.1%至1.5%,小米-W(01810.HK)及快手-W(01024.HK)高開0.5%至0.8%,嗶哩嗶哩-W(09626.HK)高開4.5%,百度-SW(09888.HK)則低開1.2%。
晶片股中芯(00981.HK)第四季純利1.75億美元,按季增長86%,惟股價低開2.6%。車股吉利(00175.HK)及比亞迪(01211.HK)高開1.8%,蔚來-SW(09866.HK)及小鵬-W(09868.HK)高開4.4%及2.5%。
金融股方面,匯控(00005.HK)高開0.5%報62元,港交所(00388.HK)高開1.7%報247.8元,友邦(01299.HK)高開4%報64.8元,中國平安(02318.HK)高開1.9%報34.7元。
藥明系顯著炒高,藥明生物(02269.HK)及藥明康德(02359.HK)高開7.4%及6.1%。中生製藥(01177.HK)出售正大青島67%,對價18億人民幣,股價高開0.7%。信達生物(01801.HK)上季總產品收入按年增長逾65%,股價高開1.8%。
富力(02777.HK)可能出售英物業實現淨收益近31億元,股價高開4.9%。中海外(00688.HK)1月系內合約銷售按年跌20%,股價高開0.8%。潤地(01109.HK)證實將進行重大組織架構調整,股價高開0.4%。
百勝中國(09987.HK)全年純利升87%,派末期息16美仙,擬斥12.5億美元回購,股價高開15%,報333.4港元。思捷環球(00330.HK)料上年度淨虧損擴至19億元,股價低開4.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.